Computational and biophysical validation of tobramycin targeting Mycobacterium MetE(Rv1133c): implications for anti-tuberculosis activity & rifampicin synergy.
The global escalation of multidrug-resistant tuberculosis (MDR-TB) demands identification of novel therapeutic targets. Here, we establish Vitamin B12-independent methionine synthase E 'MetE' (Rv1133c) as a crucial drug target and validate tobramycin as its inhibitor. Through a multi-faceted approach, including virtual...